ATE513541T1 - Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin - Google Patents

Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin

Info

Publication number: ATE513541T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; calcitonin; pharmacologically active; oral administration; agent
Prior art date: 2000-12-06

Application number

AT01985368T

Other languages

English (en)

Inventor

Joseph Ault

Moise Azria

Simon Bateman

Joseph Sikora

Gregory Sparta

Rebecca Yang

Jie Xiao

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-06

Filing date

2001-12-05

Publication date

2011-07-15

2001-12-05 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE513541T1 publication Critical patent/ATE513541T1/de

Links

102000055006 Calcitonin Human genes 0.000 title abstract 2
108060001064 Calcitonin Proteins 0.000 title abstract 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title abstract 2
229960004015 calcitonin Drugs 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000013543 active substance Substances 0.000 abstract 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 2
229960000913 crospovidone Drugs 0.000 abstract 1
229940124447 delivery agent Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
229940069328 povidone Drugs 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Rheumatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Orthopedic Medicine & Surgery (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01985368T 2000-12-06 2001-12-05 Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin ATE513541T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25172900P	2000-12-06	2000-12-06
PCT/EP2001/014294 WO2002045754A2 (en)	2000-12-06	2001-12-05	Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Publications (1)

Publication Number	Publication Date
ATE513541T1 true ATE513541T1 (de)	2011-07-15

Family

ID=22953160

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01985368T ATE513541T1 (de)	2000-12-06	2001-12-05	Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin

Country Status (26)

Country	Link
US (1)	US7049283B2 (de)
EP (1)	EP1341526B1 (de)
JP (2)	JP4898078B2 (de)
KR (1)	KR100847695B1 (de)
CN (1)	CN1304048C (de)
AT (1)	ATE513541T1 (de)
AU (2)	AU3454702A (de)
BR (2)	BRPI0115965B1 (de)
CA (1)	CA2436599C (de)
CY (1)	CY1112562T1 (de)
CZ (1)	CZ305418B6 (de)
DK (1)	DK1341526T3 (de)
EC (1)	ECSP034639A (de)
ES (1)	ES2367009T3 (de)
HU (1)	HU230632B1 (de)
IL (2)	IL155992A0 (de)
MX (1)	MXPA03005096A (de)
NO (1)	NO332936B1 (de)
NZ (1)	NZ526196A (de)
PL (1)	PL209703B1 (de)
PT (1)	PT1341526E (de)
RU (1)	RU2287999C2 (de)
SI (1)	SI1341526T1 (de)
SK (1)	SK287613B6 (de)
WO (1)	WO2002045754A2 (de)
ZA (1)	ZA200304295B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ534409A (en) *	1999-04-05	2006-03-31	Emisphere Tech Inc	Disodium salts, monohydrates, and ethanol solvates for delivering active agents
CA2446929C (en) *	2001-06-01	2013-04-09	Novartis Ag	Orally administering parathyroid hormone and calcitonin
US20050054557A1 (en) *	2002-05-09	2005-03-10	Goldberg Michael M.	Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) *	2002-07-17	2004-03-01	Novartis Ag	Use of organic compounds
PE20040724A1 (es) *	2002-08-01	2004-12-06	Novartis Ag	Composicion para la administracion oral de calcitonina
PL1603553T3 (pl) *	2003-03-17	2012-04-30	Japan Tobacco Inc	Kompozycje farmaceutyczne inhibitorów CETP
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
PT1651248E (pt) *	2003-07-11	2009-11-10	Novartis Ag	Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
PL1651249T3 (pl) *	2003-07-23	2013-04-30	Novartis Ag	Zastosowanie kalcytoniny w zapaleniu kości i stawów
EP1663182B2 (de) *	2003-09-12	2019-11-20	Amgen Inc.	SCHNELL AUFLÖSENDE FORMULIERUNG VON CINACALCET HCl
NZ551597A (en) *	2004-05-19	2010-11-26	Emisphere Tech Inc	Topical cromolyn formulations
GB0422644D0 (en) *	2004-10-12	2004-11-10	Novartis Ag	Organic compounds
GB0427603D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
US20080153779A1 (en) *	2005-02-01	2008-06-26	Jun Liao	Gastric Retention and Controlled Release Delivery System
WO2007005995A2 (en) *	2005-07-05	2007-01-11	Emisphere Technologies, Inc.	Compositions for buccal delivery of human growth hormone
AU2006292337B8 (en)	2005-09-19	2013-02-07	Emisphere Technologies, Inc.	Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
GB0522566D0 (en)	2005-11-04	2005-12-14	Novartis Ag	Organic compounds
US20080255048A1 (en) *	2005-11-17	2008-10-16	Moise Azria	Pharmaceutical Composition
EP1991241A4 (de) *	2006-02-23	2009-07-08	Iomedix Sleep Internat Srl	Zusammensetzungen und verfahren zur einleitung und aufrechterhaltung von hochwertigem schlaf
AU2007284801A1 (en) *	2006-08-08	2008-02-21	The Regents Of The University Of Californina	Salicylanilides enhance oral delivery of therapeutic peptides
KR101524880B1 (ko) *	2006-08-31	2015-06-01	노파르티스 아게	Ｈｇｈ를 포함하는 경구 전달용 제약 조성물
CA2572004A1 (en) *	2006-12-08	2008-06-08	Bernard Charles Sherman	Tablets comprising entacapone and crospovidone
ES2365648T3 (es) *	2007-03-02	2011-10-07	Novartis Ag	Administración oral de una calcitonina.
WO2009059188A1 (en)	2007-11-02	2009-05-07	Emisphere Technologies, Inc.	Method of treating vitamin b12 deficiency
CN102123697B (zh) *	2008-08-18	2015-06-10	安特拉贝欧有限公司	用于口服给予蛋白质的方法和组合物
EP2762150A1 (de) *	2009-03-12	2014-08-06	Nordic Bioscience A/S	Behandlung von Diabetes und Stoffwechselsyndrom
KR101811376B1 (ko) *	2010-06-09	2017-12-22	에미스페어 테크놀로지스, 인코포레이티드	경구용 철 결핍증 치료
MX345501B (es)	2010-12-16	2017-02-02	Novo Nordisk As	Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
KR101972836B1 (ko)	2011-04-12	2019-04-29	노보 노르디스크 에이/에스	이중 아실화된 ｇｌｐ-1 유도체
EP2827885B1 (de)	2012-03-22	2018-08-15	Novo Nordisk A/S	Zusammensetzungen von glp-1-peptiden und ihre herstellung
HRP20190489T1 (hr)	2012-03-22	2019-05-03	Novo Nordisk A/S	Pripravci koji sadrže sredstvo za unošenje i njihova priprava
WO2013139695A1 (en)	2012-03-22	2013-09-26	Novo Nordisk A/S	Compositions comprising a delivery agent and preparation thereof
US9993430B2 (en)	2012-06-20	2018-06-12	Novo Nordisk A/S	Tablet formulation comprising semaglutide and a delivery agent
SMT201800492T1 (it)	2013-05-02	2018-11-09	Novo Nordisk As	Dosaggio orale di composti di glp-1
CN104961687B (zh) *	2015-06-03	2017-07-25	苏州维泰生物技术有限公司	1,2‑二嗪衍生物及其制剂、用途
BR112017022857B1 (pt) *	2015-07-08	2023-09-26	Research & Business Foundation Sungkyunkwan University	Composto, método para preparar o composto, uso de uma composição
WO2017064538A1 (en) *	2015-10-16	2017-04-20	Nobel Ilac Sanayii Ve Ticaret A.S.	Pharmaceutical compositions of nilotinib hydrochloride
CN107080739A (zh) *	2017-04-17	2017-08-22	深圳市泛谷药业股份有限公司	一种用于口服给药的固体快速释放布南色林片及其制备方法
EP4299118A3 (de)	2018-02-02	2024-04-10	Novo Nordisk A/S	Feste zusammensetzungen mit einem glp-1-agonisten, einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure und einem schmierstoff
JP2021054781A (ja) *	2019-09-26	2021-04-08	デボンエルエス，リミテッド	共結晶形エフィナコナゾール、及びその製造方法
KR102301743B1 (ko) *	2020-12-29	2021-09-13	대봉엘에스 주식회사	에피나코나졸 경구용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5015633A (en)	1987-04-27	1991-05-14	E. R. Squibb & Sons, Inc.	Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en)	1987-09-15	1998-05-26	Novartis Corporation	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en)	1989-02-06	1991-03-26	Rorer Pharmaceutical Corp.	Calcitonin suppository formulations
IT1238072B (it)	1990-01-19	1993-07-03	Sclavo Spa	Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH052771A (ja) *	1991-06-25	1993-01-08	Pioneer Electron Corp	光記録媒体
US5681811A (en) *	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
EP0800384B1 (de)	1994-12-14	2001-03-07	Enbalt Trading Limited	Pharmazeutische zubereitung zur direktverpressung
BR9604880A (pt) *	1995-03-31	1998-05-19	Emisphere Tech Inc	Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en)	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5912014A (en) *	1996-03-15	1999-06-15	Unigene Laboratories, Inc.	Oral salmon calcitonin pharmaceutical products
US5972381A (en)	1996-06-28	1999-10-26	Schering Corporation	Solid solution of an antifungal agent with enhanced bioavailability
EP0839526A3 (de) *	1996-10-31	1999-01-07	Takeda Chemical Industries, Ltd.	Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften
US5773647A (en)	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
JP4975201B2 (ja)	1997-02-07	2012-07-11	エミスフェアー・テクノロジーズ・インク	化合物及び活性剤を送達するための組成物
RO121834B1 (ro)	1998-03-16	2008-06-30	Inhale Therapeutic Systems, Inc.	Dispozitiv pentru administrarea unui agent activ
WO2000057857A1 (en)	1999-03-25	2000-10-05	Yuhan Corporation	Rapidly disintegrable tablet for oral administration
NZ534409A (en) *	1999-04-05	2006-03-31	Emisphere Tech Inc	Disodium salts, monohydrates, and ethanol solvates for delivering active agents
WO2000059480A1 (en) *	1999-04-05	2000-10-12	Emisphere Technologies, Inc.	Lyophilized solid dosage forms and methods of making

2001
- 2001-12-04 US US10/006,311 patent/US7049283B2/en not_active Expired - Fee Related
- 2001-12-05 AT AT01985368T patent/ATE513541T1/de active
- 2001-12-05 PL PL362247A patent/PL209703B1/pl unknown
- 2001-12-05 AU AU3454702A patent/AU3454702A/xx active Pending
- 2001-12-05 PT PT01985368T patent/PT1341526E/pt unknown
- 2001-12-05 CN CNB018201423A patent/CN1304048C/zh not_active Expired - Fee Related
- 2001-12-05 HU HU0302319A patent/HU230632B1/hu not_active IP Right Cessation
- 2001-12-05 KR KR1020037007098A patent/KR100847695B1/ko not_active Expired - Fee Related
- 2001-12-05 EP EP01985368A patent/EP1341526B1/de not_active Expired - Lifetime
- 2001-12-05 AU AU2002234547A patent/AU2002234547B2/en not_active Ceased
- 2001-12-05 RU RU2003119545/15A patent/RU2287999C2/ru not_active IP Right Cessation
- 2001-12-05 SI SI200130999T patent/SI1341526T1/sl unknown
- 2001-12-05 WO PCT/EP2001/014294 patent/WO2002045754A2/en not_active Ceased
- 2001-12-05 DK DK01985368.8T patent/DK1341526T3/da active
- 2001-12-05 MX MXPA03005096A patent/MXPA03005096A/es active IP Right Grant
- 2001-12-05 CA CA2436599A patent/CA2436599C/en not_active Expired - Fee Related
- 2001-12-05 SK SK688-2003A patent/SK287613B6/sk not_active IP Right Cessation
- 2001-12-05 BR BRPI0115965-8A patent/BRPI0115965B1/pt unknown
- 2001-12-05 ES ES01985368T patent/ES2367009T3/es not_active Expired - Lifetime
- 2001-12-05 CZ CZ2003-1566A patent/CZ305418B6/cs not_active IP Right Cessation
- 2001-12-05 JP JP2002547536A patent/JP4898078B2/ja not_active Expired - Fee Related
- 2001-12-05 BR BR0115965-8A patent/BR0115965A/pt not_active IP Right Cessation
- 2001-12-05 IL IL15599201A patent/IL155992A0/xx active IP Right Grant
- 2001-12-05 NZ NZ526196A patent/NZ526196A/en not_active IP Right Cessation
2003
- 2003-05-19 IL IL155992A patent/IL155992A/en not_active IP Right Cessation
- 2003-06-02 ZA ZA200304295A patent/ZA200304295B/en unknown
- 2003-06-03 NO NO20032511A patent/NO332936B1/no not_active IP Right Cessation
- 2003-06-04 EC EC2003004639A patent/ECSP034639A/es unknown
2009
- 2009-04-13 JP JP2009097262A patent/JP2009185052A/ja not_active Withdrawn
2011
- 2011-08-09 CY CY20111100759T patent/CY1112562T1/el unknown

Also Published As

Publication number	Publication date
CY1112562T1 (el)	2016-02-10
HUP0302319A3 (en)	2013-04-29
AU3454702A (en)	2002-06-18
JP2009185052A (ja)	2009-08-20
ES2367009T3 (es)	2011-10-27
DK1341526T3 (da)	2011-10-03
EP1341526B1 (de)	2011-06-22
IL155992A (en)	2008-04-13
BRPI0115965B1 (pt)	2017-09-26
AU2002234547B2 (en)	2005-03-24
PL362247A1 (en)	2004-10-18
NO332936B1 (no)	2013-02-04
MXPA03005096A (es)	2003-09-05
EP1341526A2 (de)	2003-09-10
HK1059565A1 (en)	2004-07-09
KR20040018309A (ko)	2004-03-03
WO2002045754A3 (en)	2003-01-03
ECSP034639A (es)	2003-07-25
US20020123459A1 (en)	2002-09-05
KR100847695B1 (ko)	2008-07-23
PT1341526E (pt)	2011-09-01
HUP0302319A2 (hu)	2003-11-28
US7049283B2 (en)	2006-05-23
CZ305418B6 (cs)	2015-09-09
ZA200304295B (en)	2004-05-10
RU2287999C2 (ru)	2006-11-27
HU230632B1 (hu)	2017-05-29
PL209703B1 (pl)	2011-10-31
CZ20031566A3 (cs)	2003-09-17
SK6882003A3 (en)	2004-01-08
WO2002045754A2 (en)	2002-06-13
NO20032511L (no)	2003-06-03
CA2436599A1 (en)	2002-06-13
JP2004515480A (ja)	2004-05-27
CA2436599C (en)	2011-01-25
BR0115965A (pt)	2003-10-28
IL155992A0 (en)	2003-12-23
CN1304048C (zh)	2007-03-14
NZ526196A (en)	2005-01-28
JP4898078B2 (ja)	2012-03-14
SI1341526T1 (sl)	2011-10-28
SK287613B6 (sk)	2011-04-05
NO20032511D0 (no)	2003-06-03
CN1479612A (zh)	2004-03-03

Legal Events

Date

Code

Title

Description

2012-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1341526

Country of ref document: EP

Publication	Publication Date	Title
ATE513541T1 (de)	2011-07-15	Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin
ITMI20001173A0 (it)	2000-05-26	Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
ATE442158T1 (de)	2009-09-15	Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form
BG66093B1 (bg)	2011-04-29	Състави с контролирано освобождаване, съдържащи нимесулид
DE69906518D1 (de)	2003-05-08	Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
ID27504A (id)	2001-04-12	Formulasi oral baru
DE60335426D1 (de)	2011-01-27	Pharmazeutische Zusammensetzungen enthaltend einen Opioidantagonisten
CY1111698T1 (el)	2015-10-07	Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
CY1110906T1 (el)	2015-06-10	Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
ATE252377T1 (de)	2003-11-15	Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
ATE262893T1 (de)	2004-04-15	Darreichungsformen zur behandlung von oralen mykosen
WO2003041656A3 (en)	2003-10-23	Soluble drug extended release system
BR0114395A (pt)	2005-08-16	Composição farmacêutica para administração por suprimento via oral
ATE297760T1 (de)	2005-07-15	Pharmazeutische zusammensetzungen enthaltend terbinafin
DE69904020D1 (de)	2003-01-02	Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
ATE460934T1 (de)	2010-04-15	Pharmazeutische zubereitungen von ciprofloxacin
BR0111018A (pt)	2004-02-17	Formulações estáveis lìquidas e sólidas
DE50005282D1 (de)	2004-03-18	Medikament sowie aufeinander abgestimmte kombination von medikamenten
HRP20070081T5 (hr)	2007-08-31	Nazalni farmaceutski pripravak piribedila
PA8531801A1 (es)	2003-11-12	Formulaciones estabilizadas que comprenden composiciones hidroliticamente inestables
UY27017A1 (es)	2002-06-20	Composiciones hidrolíticamente inestables